State Employee Health Plans Could Save $1.8 Billion Annually with Biosimilar Adoption
Event summary
- Pacific Research Institute study finds state employee health plans could save up to $1.8 billion annually by prioritizing biosimilars.
- Biosimilars have already generated over $56 billion in nationwide savings since their introduction.
- State employee health plans spent roughly $20 billion on originator biologic medicines in 2024.
- California alone could save up to $179 million annually with higher biosimilar adoption.
The big picture
The study highlights a significant cost-saving opportunity for states struggling with budget constraints. Biosimilars offer a rare win-win scenario where taxpayers save money, state budgets become more sustainable, and employees maintain access to effective treatments. This aligns with broader industry trends toward cost containment in healthcare without compromising quality of care.
What we're watching
- Adoption Pace
- How quickly states will implement biosimilar prioritization strategies to realize savings.
- Patent Expirations
- The impact of over 100 biologic medicines losing patent protection in the next decade on savings potential.
- Policy Influence
- Whether state governments will adopt recommendations from the study to improve fiscal health of employee health plans.
Related topics